Nasdaq · Biotech stocks database

IMTX — Immatics N.V.

IMTX (Immatics N.V.) stock: $6.36, $951.7M market cap, $389.3M cash, $562.4M EV, $1.10B fully diluted market cap. Lead program: IMA203 (Melanoma, Cutaneous Malignant), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are registered in the Commercial Register of the Chamber of Commerce (Kamer van Koophandel) in the Netherlands under number 77595726. We have our corporate seat in Amsterdam, the Netherlands and our registered office is at Paul-Ehrlich-Straße 15, 72076 Tübingen, Federal Republic of Germany, and our telephone number is +49 (7071) 5397-0.

Source: 20-F FY2025 via SEC EDGAR

Share price

$6.36

Market cap

$951.7M

Cash

$389.3M

Enterprise value

$562.4M

Balance sheet

Cash	$389.3M
Debt	$0.0M
Net cash	$389.3M
Enterprise value	$562.4M
Basic shares	149.6M shares
Fully diluted shares	172.5M shares
Fully diluted market cap	$1,097.0M
Cash per share	$2.60

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

149.6M

Pre-funded warrants

4.3M

Options

17.3M

RSUs

1.2M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

172.5M

Cap table as of 2025-12-31.

Price history

Loading IMTX daily closes…

Loading price history…

Next catalyst

anzu-cel (anzutresgene autoleucel, IMA203) · Est. Apr 1, 2027 · half midpoint · guided in 8 wks

Recently reported

IMA402 Phase 1 Mixed · 2026-10-24

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	anzu-cel (anzutresgene autoleucel, IMA203) Phase 3 SUPRAME in advanced melanoma	Phase 3	advanced melanoma	H1 2027
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	IMA402 + IMA401 Phase 1b bispecific combination in squamous NSCLC	Phase 1b	squamous NSCLC	2027
Oct 13 - Nov 24 in 11 mo	IMA402	Phase 1/2	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	—
Feb 12 - Mar 25 in 15 mo	IMA203	Phase 3	Melanoma, Cutaneous Malignant	—
Jan 12 - Feb 23 in 27 mo	IMA203 Product	Phase 1/2	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	ESMO Congress 2026
Sep 12 - Oct 24 in 35 mo	IMA203	Phase 1	Cutaneous Melanoma; Synovial Sarcoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	IMA203
Lead indication	Melanoma, Cutaneous Malignant
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06743126	Phase 3	Recruiting	Sponsor	Immatics US, Inc.	—	Melanoma, Cutaneous Malignant	H1 2027 Est. Apr 1, 2027 · half midpoint
NCT05958121	Phase 1/2	Recruiting	Sponsor	Immatics Biotechnologies GmbH	—	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	—
NCT03686124	Phase 1/2	Recruiting	Sponsor	Immatics US, Inc.	—	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	ESMO Congress 2026
NCT06946225	Phase 1	Recruiting	Sponsor	Immatics US, Inc.	—	Cutaneous Melanoma; Synovial Sarcoma	—
NCT05359445	Phase 1	Active, not recruiting	Sponsor	Immatics Biotechnologies GmbH	—	Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Immatics US, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	12,946,176	+76,836	1.12%	2026-08-14
Perceptive Advisors	10,383,456	no change	1.63%	2026-08-14
Baker Bros. Advisors	9,508,565	-1,408,128	0.48%	2026-08-14
Sphera Biotech	720,057	+23,952	1.04%	2026-08-14
Boxer Capital	475,000	+475,000	0.36%	2026-08-14
DAFNA Capital	116,960	-108,900	0.23%	2026-08-14
Ikarian Capital	48,569	no change	0.08%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.

Subscribe to Compounding Ego

IMTX — Immatics N.V.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IMTX — Immatics N.V. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IMTX — Immatics N.V.